利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1336 条记录 (耗时 0.045 秒)

    Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
    91.
    发明申请
    Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens 审中-公开
    通过柔性接头稳定的HIF-1包膜糖蛋白作为有效的入侵抑制剂和免疫原

    公开(公告)号：US20050106160A1

    公开(公告)日：2005-05-19

    申请号：US10506651

    申请日：2002-03-05

    申请人： Dimiter Dimitrov ,  Yen-Hung Chow ,  Sanjay Phogat ,  Christopher Broder

    发明人： Dimiter Dimitrov ,  Yen-Hung Chow ,  Sanjay Phogat ,  Christopher Broder

    IPC分类号： A61K39/21 ,  C07H21/04 ,  C07K14/16

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/545 ,  C07H21/04 ,  C12N2740/16122 ,  C12N2740/16134

    摘要： This invention relates generally to immune responses to human immunodeficiency virus coat protein gp160 presented in the form of antigenic compositions, nucleic acids encoding human immunodeficiency virus coat proteins, and vaccines. The invention also relates to methods for production of antigenic compositions containing human immunodeficiency virus coat protein, nucleic acids encoding human immunodeficiency virus coat proteins, and human immunodeficiency virus vaccines. The invention comprises gp120 and gp41 subunits of the human immunodeficiency virus coat protein covalently linked through a peptide linker, as well as additional complexes including those comprising the human immunodeficiency virus coat protein and it's natural cellular receptor molecules.

    摘要翻译： 本发明一般涉及抗原组合物形式的人免疫缺陷病毒外壳蛋白gp160的免疫应答，编码人免疫缺陷病毒外壳蛋白的核酸和疫苗。 本发明还涉及含有人免疫缺陷病毒外壳蛋白，编码人免疫缺陷病毒外壳蛋白的核酸和人免疫缺陷病毒疫苗的抗原组合物的制备方法。 本发明包括通过肽接头共价连接的人免疫缺陷病毒外壳蛋白的gp120和gp41亚基，以及包括人免疫缺陷病毒外壳蛋白和其天然细胞受体分子的其它复合物。

    Mutated env gene, mutated env glycoprotein and the use thereof
    93.
    发明申请
    Mutated env gene, mutated env glycoprotein and the use thereof 审中-公开
    突变的env基因，突变的env糖蛋白及其用途

    公开(公告)号：US20050065320A1

    公开(公告)日：2005-03-24

    申请号：US10487094

    申请日：2002-09-06

    申请人： Frederic Bedin ,  Frederic Beynard ,  Bernard Verbier ,  Yasemin Ataman-Onal

    发明人： Frederic Bedin ,  Frederic Beynard ,  Bernard Verbier ,  Yasemin Ataman-Onal

    IPC分类号： C12N15/09 ,  A61K39/00 ,  A61P31/18 ,  C07K14/16 ,  C12N15/48 ,  C07H21/04 ,  C12N7/00 ,  C12N15/867 ,  C12Q1/70

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/53 ,  C12N2740/16122

    摘要： The invention relates to a mutated env gene which codes for a mutated envelope glycoprotein of virus HIV-1. In relation to the env gene of a reference or primary infection primary isolate, said gene presents at least two mutations at the glycosylation sites which are preserved from one primary isolate to another. Each mutation consists in the replacement of an AAC or AAT codon which codes for an asparagine with a CAG or CAA codon which codes for a glutamine, the two mutations at least being selected from the following: (a) at least two mutations in the part of the env gene that codes for region C3 of the env protein; (b) at least one mutation in the part that codes for region C3 and at least one mutation in the part that codes for region V3; (c) at least one mutation in the part that codes for region C2 and at least one mutation in the part that codes for region V3 chosen from the glycosylation sites at codons 862-864 and 970-972; (d) at least one mutation in the part that codes for region C2 selected from the glycosylation sites at codons 667-669, 679-681, 700-702,763-765, 844-846 and at least one mutation in the part that codes for region V3. Alternatively, the mutated env gene consists of any one of the following sequences: SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10, or the complementary sequences thereof. The invention also relates to the mutated Env glycoprotein and the use of the gene and the glycoprotein in a pharmaceutical composition in order to produce antibodies and to evaluate a therapeutic agent.

    摘要翻译： 本发明涉及编码病毒HIV-1的突变包膜糖蛋白的突变型env基因。 关于参考或原代感染初级分离株的env基因，所述基因在糖基化位点处至少存在两个突变，其从一个主要分离物保留到另一个。 每个突变都在于替换AAC或AAT密码子，其编码具有编码谷氨酰胺的CAG或CAA密码子的天冬酰胺，所述两个突变至少从以下选择：（a）部分中的至少两个突变 的env基因编码env蛋白的区域C3; （b）编码区域C3的部分中的至少一个突变和编码区域V3的部分中的至少一个突变; （c）在编码区域C2的部分中至少有一个突变，以及编码从密码子862-864和970-972处的糖基化位点选择的区域V3的部分中的至少一个突变; （d）编码选自密码子667-669,679-681,700-702,763-765,844-846的糖基化位点的区域C2部分中的至少一个突变，以及编码 区域V3。 或者，突变的env基因由以下序列之一组成：SEQ ID NO：8，SEQ ID NO：9或SEQ ID NO：10，或其互补序列。 本发明还涉及突变的Env糖蛋白以及药物组合物中基因和糖蛋白在产生抗体中的用途以及评价治疗剂。

    Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection
    94.
    发明申请
    Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection 审中-公开
    表达人CD4和与HIV感染相关的人融合辅助因子的细胞

    公开(公告)号：US20050064390A1

    公开(公告)日：2005-03-24

    申请号：US10638797

    申请日：2003-08-11

    申请人： Edward Berger ,  Yu Feng ,  Paul Kennedy ,  Christopher Broder

    发明人： Edward Berger ,  Yu Feng ,  Paul Kennedy ,  Christopher Broder

    IPC分类号： A61K38/00 ,  A61K48/00 ,  C07K14/715 ,  C07K16/28 ,  C12N5/08 ,  C12Q1/70 ,  C07H21/04 ,  C07K14/16 ,  C07K14/74

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  C07K16/2866

    摘要： The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (CXCR4). CXCR4 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CXCR4 plays an essential role in the membrane fusion step of HIV infection. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CXCR4 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against CXCR4, isolated and purified peptide fragments of CXCR4, and CXCR4-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

    摘要翻译： 对人体免疫缺陷病毒（HIV）感染的敏感性取决于人CD4分子的细胞表面表达和与HIV感染相关的人融合辅助因子（CXCR4）。 CXCR4是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CXCR4在HIV感染的膜融合步骤中发挥重要作用。 稳定的非人细胞系和具有共表达人CD4和CXCR4的细胞的转基因哺乳动物的建立为继续研究HIV感染和开发更有效的抗HIV治疗提供了宝贵的工具。 此外，能够阻断HIV和靶细胞之间膜融合的抗CXCR4，分离和纯化的CXCR4肽片段和CXCR4结合生物制剂的抗体代表潜在的抗HIV治疗剂。